The HIV Vaccine Program Management Office (HIVV PMO) and the Walter Reed Army Institute of Research (WRAIR) recently announced they are asking companies, educational institutions, organizations, and consortia for information about clinical research support.
The two organizations are targeting groups that can support and perform vaccine clinical research activities at facilities in Kenya, Nigeria,
Mozambique, Tanzania, Thailand, Uganda and the U.S.
With the collected information, the organizations will be able to determine the opportunity to finish clinical trials and support laboratory evidence. The goal is to support critical path studies to license future candidate vaccines.
The organizations are primarily looking for companies that can further intramural HIV vaccine candidates from the company’s tech base (both safety and immunogenicity) through advanced development (immunogenicity and efficacy) programs. Specifically, WRAIR seeks companies that can support and launch vaccine trials using heterologous prime-boost vaccination strategies containing combinations like recombinant protein immunogens and adjuvant, recombinant viral vectors, and HIV DNA plasmids.
The secondary target is to gather information about future HIV vaccine technological enhancements, such as innovations for stability and shelf life, optimizations for protective immune response, new methods to deliver and identify immunologic markers indicating protection, and effectiveness of new adjuvants.
